Vindesine effect in myeloid leukemia
- PMID: 6957273
- DOI: 10.1007/BF00254046
Vindesine effect in myeloid leukemia
Abstract
Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL). A substantial and rapid decrease of leukemic cells was obtained in 31 of 36 patients, and this was independent of cell phenotype and morphology. VDS may improve the results of polychemotherapy of ANLL, and is useful for palliative treatment of CML/BM.
Similar articles
-
[A randomized controlled study on vindesine and vincristine in combination with prednisolone in the treatment of adult acute lymphocytic leukemia and blastic crisis of chronic myeloid leukemia].Gan To Kagaku Ryoho. 1983 Dec;10(12):2500-8. Gan To Kagaku Ryoho. 1983. PMID: 6580840 Clinical Trial. Japanese.
-
[Administration of vindesine sulfate for the treatment of malignant hematological tumors].Gan To Kagaku Ryoho. 1982 Feb;9(2):306-15. Gan To Kagaku Ryoho. 1982. PMID: 6764103 Clinical Trial. Japanese.
-
[Phase II study of Vindesine in patients with hematological malignancy].Gan To Kagaku Ryoho. 1983 Jun;10(6):1536-7. Gan To Kagaku Ryoho. 1983. PMID: 6347082 Clinical Trial. Japanese.
-
Vindesine: a new vinca alkaloid.Recent Results Cancer Res. 1980;74:91-7. doi: 10.1007/978-3-642-81488-4_13. Recent Results Cancer Res. 1980. PMID: 7003662 Review.
-
Vindesine in the treatment of leukaemia.Leuk Lymphoma. 1997 Aug;26(5-6):497-506. doi: 10.3109/10428199709050886. Leuk Lymphoma. 1997. PMID: 9389357 Review.
Cited by
-
Inadvertent intrathecal application of vindesine and its neurological outcome: case report and systematic review of the literature.Brain Spine. 2025 Jun 2;5:104292. doi: 10.1016/j.bas.2025.104292. eCollection 2025. Brain Spine. 2025. PMID: 40546273 Free PMC article. Review.